Evaluation of everolimus in renal cell cancer

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1229-1240

  Amato, Robert ^a   Stepankiw, Mika ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Everolimus; Mammalian target of rapamycin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CREATININE; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DNA DAMAGE; DNA REPLICATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; DYSPNEA; EPISTAXIS; FATIGUE; GENOMICS; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LIMB PAIN; LUNG ALVEOLITIS; LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG TOXICITY; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MITOSIS; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; PROTEOMICS; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TONGUE ULCER; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG DESIGN; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84877885268     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.791677     Document Type: Review

References (56)

1. Kidney Cancer. American Cancer Society, 2013
2. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009., in Institute NC. Vintage 2009 Populations, Bethesda, MD; 2011.Available from: http://seer.cancer. gov/csr/1975-2009-pops09/
3. Motzer RJ, Bacik J, Murphy BA, et al. Interferon alfa as a comparative treatment for clinical trals of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96
4. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41
5. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-63
6. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576-83
7. Dosquet C, Coudert MC, Lepage E, et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8
8. Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7
9. Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23:4953-8
10. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112-25
11. Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol 2006;16:206-12
12. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
13. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1and 4EBP1/eukaryotic translation factor 4E. Mol Cell Biol 2004;24:200-16
14. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
15. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7
16. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006;25:6347-60
17. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science 1989;243:1564-70
18. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67
19. Crespo JL, Hall MN. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2002;66:579-91
20. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-28
21. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
22. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004;5:519-23
23. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59
24. Powis G, Kirkpatrick L. Hypoxia inducible factor-1 (alpha) as a cancer drug target. Mol Cancer Ther 2004;3:647-54
25. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl 5):10-17
26. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
27. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
29. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
30. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9
31. Kodaki T, Woscholski R, Hallberg B, et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 1994;4:798-806
32. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95
33. de Graffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10: 8059-67
34. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63
35. Application Number, Center for drug evaluation and research, office of clinical pharmacology 2003; 21-560s000
36. Everolimus-Compound Summary (CID 6442177), National Center for Biotechnology Information, PubChem BioAssay Database
37. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95
38. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95
39. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001;69:48-56
40. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001;33:514-15
41. Summary of Product Characteristics: Afinitor Tablets, Electronic Medicines Compendium; 2012
42. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-9
43. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-46
44. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65
45. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
46. Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48:333-9
47. Bracarda S, Hutson TE, Porta C, et al. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer 2012;106:1475-80
48. Porta C, Calvo E, Climent MA, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33
49. Stein A, Bellmunt J, Escudier B, et al. Survival Prediction in everolimus-treated Patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol 2012
50. Hainsworth JD, Spigel DR, Burris HA III, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28:2131-6
51. Harzstark AL, Small EJ, Weinberg VK, et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011;117:4194-200
52. Amato RJ, Flaherty AL, Stepankiw M. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin Genitourin Cancer 2012;10:26-31
53. Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012;118:1868-76
54. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182:396-403
55. Ramirez-Fort MK, Case EC, Rosen AC, et al. Rash to the mTOR inhibitor Everolimus: systematic review and meta-analysis. Am J Clin Oncol 2012; Epub ahead of print
56. Knox JJ, Kay AC, Schiff E, et al. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC) [abstract TPS232]. J Clin Oncol 2010;28(Suppl):15s